Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

Scientists have successfully zapped HIV out of infected cells — raising hopes of a cure for the chronic disease. The team from Amsterdam UMC used gene-editing technology to eliminate all traces of the ...

The Wistar Institute, a nonprofit dedicated to biomedical research, is investing $24 million to advance its efforts to identify a cure for HIV. Part of the goal in creating a center at a second ...

Since it first captured headlines in the 1980s, the human immunodeficiency virus, better known as HIV, has been a tough nut to crack. It’s not for a lack of trying, however. Science has come a long ...

B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...

Four years ago, a team of research physicians at Weill Cornell Medicine began treatment for an HIV patient, in the hopes of finding a cure. This February marked 14 months since the patient was free of ...